Immatics N.V.’s lead T-cell receptor (TCR) therapy candidate, IMA203, is two months away from entering Phase III development as the company announced positive Phase Ib data in metastatic melanoma. The drug would compete against an existing cell therapy option, but has an entirely different mechanism of action.
Immatics Off To Phase III With IMA203 After Positive Melanoma Results
The TCR therapy showed strong efficacy and durability in patients with previously treated melanoma. A Phase III pivotal trial is due to start in December.
